Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran; Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Department of Lab Science, Sirjan School of Medical Sciences, Sirjan, Iran.
Indian J Med Microbiol. 2021 Jan;39(1):104-115. doi: 10.1016/j.ijmmb.2020.10.004. Epub 2020 Nov 4.
In December 2019, a novel pneumonia related to the 2019 coronavirus unexpectedly developed in Wuhan, China. We aimed to review data of the novel Coronavirus (2019-nCoV) by analyzing all the published retrospective studies on the clinical, epidemiological, laboratory, and radiological characteristics of patients with 2019-nCoV.
We searched in four bibliographic databases PubMed, Scopus, Embase, and Web of Science) for studies March 10, 2020 focused on the clinical, epidemiological, laboratory, and radiological characteristics of patients with 2019-nCoV for meta-analysis. The Newcastle-Ottawa Scale was used to quality assessment, and publication bias was analyzed by Egger's test. In the meta-analysis, a random-effects model with Stata/SE software, v.14.1 (StataCorp, College Station, TX) was used to obtain a pooled incidence rate.
Fifty studies were included in this systematic review and meta-analysis with 8815 patients and the mean age was 46 years and 4647 (52.7%) were male. The pooled incidences rate of clinical symptoms were: fever (83%, 95% CI: 0.77, 0.89), cough (59%, 95% CI: 0.48, 0.69), myalgia or fatigue (31%, 95% CI: 0.23, 0.39), sputum production (29%, 95% CI: 0.21, 0.39), and dyspnea (19%, 95% CI: 0.12, 0.26). The pooled incidence rate of acute respiratory distress syndrome (ARDS) was (22%, 95% CI: 0.00, 0.60).
The results of this systemic review and meta-analysis present a quantitative pooled incidence rate of different characters of 2019-nCoV and has great potential to develop diagnosis and patient's stratification in 2019-nCoV. However, this conclusions of this study still requisite to be warranted by more careful design, larger sample size multivariate studies to corroborate the results of this meta-analysis.
2019 年 12 月,一种新型肺炎与 2019 年冠状病毒在武汉突然出现。我们旨在通过分析所有已发表的关于 2019 年冠状病毒患者临床、流行病学、实验室和影像学特征的回顾性研究,来回顾新型冠状病毒(2019-nCoV)的数据。
我们在四个文献数据库(PubMed、Scopus、Embase 和 Web of Science)中检索了 2020 年 3 月 10 日之前发表的关于 2019-nCoV 患者临床、流行病学、实验室和影像学特征的研究,进行荟萃分析。采用纽卡斯尔-渥太华量表进行质量评估,并采用 Egger 检验分析发表偏倚。在荟萃分析中,采用 Stata/SE 软件 v14.1(StataCorp,德克萨斯州学院站)的随机效应模型来获得汇总发病率。
这项系统评价和荟萃分析共纳入 50 项研究,共 8815 例患者,平均年龄为 46 岁,其中 4647 例(52.7%)为男性。临床症状的汇总发病率为:发热(83%,95%可信区间:0.77,0.89)、咳嗽(59%,95%可信区间:0.48,0.69)、肌痛或疲劳(31%,95%可信区间:0.23,0.39)、咳痰(29%,95%可信区间:0.21,0.39)和呼吸困难(19%,95%可信区间:0.12,0.26)。急性呼吸窘迫综合征(ARDS)的汇总发病率为(22%,95%可信区间:0.00,0.60)。
这项系统评价和荟萃分析的结果呈现了 2019-nCoV 不同特征的定量汇总发病率,对于 2019-nCoV 的诊断和患者分层具有很大的潜力。然而,这项研究的结论仍需要通过更精心设计、更大样本量的多变量研究来证实,以验证本荟萃分析的结果。